Many current and emerging drug therapies suffer from poor oral bioavailability. This results in either the development of a less desirable, non-oral route of administration, complicated oral administration regimens, or the complete discontinuation of product development.

TSRL, Inc. is developing novel antiviral analogues of proven therapeutics with initial focus on influenza.Our two lead candidates (TSR-026 and TSR-462) are orally available influenza therapeutics with high potency against oseltamivir-resistant strains.These therapeutics can be deployed for treatment and prevention of seasonal and pandemic flu outbreaks.

TSRL will partner their influenza therapeutics with a larger company for clinical development and continue to focus on generating additional pre-clinical product opportunities around its transporter targeted drug design.